Antihypertensive Therapies and Cognitive Function: a Review

Current Hypertension Reports

Volumn 17, Issue 10, 2015, Pages

  Kherada, Nisharahmed ^a   Heimowitz, Todd ^a   Rosendorff, Clive ^b  

^a Department of Cardiology Mount Sinai Medical Center Columbia University ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer s disease; Antihypertensive therapies; Cognition; Dementia; Stroke

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE; INDAPAMIDE; NIMODIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DEMENTIA; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME INHIBITION; EPISODIC MEMORY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIFE EXPECTANCY; MENTAL DETERIORATION; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHORT TERM MEMORY; ANIMAL; PATHOPHYSIOLOGY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; COGNITION; COGNITION DISORDERS; HUMANS; HYPERTENSION; QUALITY OF LIFE; RISK FACTORS;

EID: 84940202365     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0592-7     Document Type: Review

References (70)

1. Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk factors for Alzheimer’s disease. Am J Geriatr Cardiol. 2007;16(3):143–9.
2. Gasecki D et al. Hypertension, brain damage and cognitive decline. Curr Hypertens Rep. 2013;15(6):547–58. A review discussing the link between HTN brain functional and structural changes, and to cognitive decline and dementia and the role of antihypertensive therapies in prevention of cognitive decline.
3. Wimo A et al. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9(1):1–11. e3.
4. Frishman WH. Are antihypertensive agents protective against dementia? a review of clinical and preclinical data. Heart Dis. 2002;4(6):380–6.
5. MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765–74.
6. Gorelick PB et al. Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. J Am Soc Hypertens. 2012;6(5):309–15.
7. Alrawi YA et al. Pharmacological blood pressure lowering in the older hypertensive patients may lead to cognitive impairment by altering neurovascular coupling. Med Hypotheses. 2013;80(3):303–7.
8. Hajjar I et al. Hypertension and cerebral vasoreactivity: a continuous arterial spin labeling magnetic resonance imaging study. Hypertension. 2010;56(5):859–64.
9. Hajjar I et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the cardiovascular health study. Circulation. 2011;123(8):858–65.
10. Hofman A et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet. 1997;349(9046):151–4.
11. Appelman AP et al. White matter lesions and lacunar infarcts are independently and differently associated with brain atrophy: the SMART-MR study. Cerebrovasc Dis. 2010;29(1):28–35.
12. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666.
13. Waldstein SR et al. Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension. 2008;51(1):99–104.
14. Nation DA et al. Elevated pulse pressure is associated with age-related decline in language ability. J Int Neuropsychol Soc. 2010;16(5):933–8.
15. Gustafson DR et al. The ACE insertion deletion polymorphism relates to dementia by metabolic phenotype, APOEepsilon4, and age of dementia onset. Neurobiol Aging. 2010;31(6):910–6.
16. Diz DI, Lewis K. Dahl memorial lecture: the renin-angiotensin system and aging. Hypertension. 2008;52(1):37–43.
17. Kehoe PG, Passmore PA. The renin-angiotensin system and antihypertensive drugs in Alzheimer’s disease: current standing of the angiotensin hypothesis? J Alzheimers Dis. 2012;30 Suppl 2:S251–68. A recent article reviews current evidence on effect of ACE-inhibitors and ARBs in treatment of AD.
18. Elias MF et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993;138(6):353–64.
19. Whitmer RA et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277–81.
20. Launer LJ et al. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274(23):1846–51.
21. Launer LJ et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49–55.
22. Yamada M et al. Association between dementia and midlife risk factors: the Radiation Effects Research Foundation Adult Health Study. J Am Geriatr Soc. 2003;51(3):410–4.
23. Skoog I et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141–5.
24. Kilander L et al. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31(3):780–6.
25. Mahoney JR et al. Alerting, orienting, and executive attention in older adults. J Int Neuropsychol Soc. 2010;16(5):877–89.
26. Nilsson SE et al. Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older. Aging Clin Exp Res. 2007;19(1):41–7.
27. Tzourio C et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163(9):1069–75.
28. Obisesan TO. Hypertension and cognitive function. Clin Geriatr Med. 2009;25(2):259–88.
29. Forette F et al. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046–52.
30. No authors listed. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24)3255–64.
31. Lithell H et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875–86.
32. Peters R et al. Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683–9.
33. Prince MJ et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s trial of hypertension in older adults. BMJ. 1996;312(7034):801–5.
34. Anderson C et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011;10(1):43–53.
35. McGuinness B et al. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev. 2006;2:CD004034.
36. Inaba S et al. Exaggeration of focal cerebral ischemia in transgenic mice carrying human renin and human angiotensinogen genes. Stroke. 2009;40(2):597–603.
37. Inaba S et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension. 2009;53(2):356–62.
38. Yagi S et al. Renin-angiotensin-aldosterone system has a pivotal role in cognitive impairment. Hypertens Res. 2013;36(9):753–8.
39. Pihlaja R et al. Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes. Glia. 2011;59(11):1643–57.
40. Kehoe PG, Wilcock GK. Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol. 2007;6(4):373–8.
41. Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J Mol Med. 2008;86(6):715–22.
42. Ciobica A et al. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg. 2009;109(3):171–80.
43. Savaskan E et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia. Neurobiol Aging. 2001;22(4):541–6.
44. Starr JM, Whalley LJ, Deary IJ. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am Geriatr Soc. 1996;44(4):411–5.
45. Ohrui T et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004;63(7):1324–5.
46. Chrysant SG. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. J Clin Hypertens (Greenwich). 2007;9(6):454–9.
47. Fournier A et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother. 2009;9(9):1413–31.
48. Fogari R et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol. 2004;59(12):863–8.
49. Fogari R et al. Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens. 2006;20(3):177–85.
50. Li NC et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.
51. Levi Marpillat N et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31(6):1073–82. A network meta-analysis showing class difference of antihypertensive therapies on beneficial effects on cognitive decline and prevention of dementia, with ARBs possibly being the most effective.
52. Ito S et al. Renin-angiotensin system in the brain as a new target of antihypertensive therapy. Hypertens Res. 2008;31(8):1487–8.
53. Takeda R et al. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Investig. 1995;18(5):370–3.
54. Yagi S et al. High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res. 2011;34(1):74–8.
55. Khachaturian AS et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63(5):686–92.
56. Yasar S et al. Diuretic use is associated with better learning and memory in older adults in the Ginkgo Evaluation of Memory Study. Alzheimers Dement. 2012;8(3):188–95.
57. Toescu EC, Xiong J. Metabolic substrates of neuronal aging. Ann N Y Acad Sci. 2004;1019:19–23.
58. Trompet S et al. Use of calcium antagonists and cognitive decline in old age. The Leiden 85-plus study. Neurobiol Aging. 2008;29(2):306–8.
59. Sze KH et al. Effect of nimodipine on memory after cerebral infarction. Acta Neurol Scand. 1998;97(6):386–92.
60. Pantoni L et al. The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci. 2000;175(2):116–23.
61. Arrieta-Cruz I et al. Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer’s disease. J Alzheimers Dis. 2010;21(2):649–54.
62. Wang J et al. Carvedilol as a potential novel agent for the treatment of Alzheimer’s disease. Neurobiol Aging. 2011;32(12):2321. e1-12.
63. Dobarro M et al. Propranolol restores cognitive deficits and improves amyloid and tau pathologies in a senescence-accelerated mouse model. Neuropharmacology. 2013;64:137–44.
64. Madden DJ, Blumenthal JA, Ekelund LG. Effects of beta-blockade and exercise on cardiovascular and cognitive functioning. Hypertension. 1988;11(5):470–6.
65. Fogari R et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens. 2003;17(11):781–5.
66. Yasar S et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology. 2013;81(10):896–903. A recent study showing antihypertensive therapies reducing risk of AD dementia independent of mean systolic blood pressure.
67. Gelber RP et al. Antihypertensive medication use and risk of cognitive impairment: the Honolulu-Asia Aging Study. Neurology. 2013;81(10):888–95. A recent community-based study showing beneficial effect of beta-blockers in prevention of cognitive decline in elderly >75 years.
68. Di Bari M et al. Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial. Am J Epidemiol. 2001;153(1):72–8.
69. Douiri A et al. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation. 2013;128(12):1341–8. A recent large community based study indicating post stroke preventive antihypertensive therapy and long-term reduced risk of cognitive impairment.
70. Ambrosius WT et al. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014;11(5):532–46. An ongoing RCT evaluating impact of optimal blood pressure control (120 versus 140 mmHg systolic) on multiple clinical endpoints including cognitive function.